Modern Diagnostic & Research Centre Ltd - 544673 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 & 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Modern Diagnostic & Research Centre board approved audited financial results for FY26. Revenue increased 6.6% YoY to ₹83.11 crore, while net profit declined 41.7% YoY to ₹5.25 crore. The auditors provided an unmodified opinion on the results.
May 29 2026 14:40:19
Modern Diagnostic & Research Centre Ltd - 544673 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) Regulations, 2015
Modern Diagnostic & Research Centre's Board of Directors is scheduled to meet on May 29, 2026. The primary agenda includes considering and approving the annual financial statements for the fiscal year ended March 31, 2026.
May 21 2026 17:22:30
Modern Diagnostic & Research Centre Ltd - 544673 - Disclosure Under Regulation 41(4) Of SEBI (Issue Of Capital And Disclosure Requirements) Regulations, 2018 For The Year Ended 31St March, 2026
Modern Diagnostic reported that Rs.17.45 crore, or 47% of its Rs.36.89 crore IPO proceeds, remained unutilised by Q4 FY26. Delays were noted in capital expenditure deployment due to location changes and supplier issues.
May 15 2026 14:42:35
Modern Diagnostic & Research Centre Ltd - 544673 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 & 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Modern Diagnostic & Research Centre's board on May 13, 2026, approved extending the timeframe for utilizing net issue proceeds and allocating funds for working capital. The meeting also addressed a temporary system shutdown due to hardware/software faults, which have since been restored.
May 13 2026 12:06:52
Modern Diagnostic & Research Centre Ltd - 544673 - Board Meeting Intimation for Intimation Of Board Meeting
Modern Diagnostic & Research Centre board will meet on May 13, 2026. The agenda includes considering an extension for net issue proceeds utilization and approving the use of General Corporate Purpose funds for working capital requirements.
May 12 2026 17:33:06
Read More